Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used
Blood Research
;
: 233-241, 2016.
Article
in English
| WPRIM
| ID: wpr-167173
ABSTRACT
BACKGROUND:
Different criteria have been used to diagnose mixed-phenotype acute leukemia (MPAL), which has impacted the number of individuals diagnosed with this pathology. Better outcomes have been reported when using acute lymphoblastic leukemia (ALL)-type chemotherapy in the treatment of MPAL.METHODS:
We compared the outcome of 4 groups of patients with MPAL. Group 1 included patients diagnosed using the 2008/2016 World Health Organization (WHO) classification; group 2 included patients diagnosed using the European Group for the Immunological Characterization of Leukemias (EGIL) criteria; group 3 included patients diagnosed using either the EGIL or the 2008/2016 WHO criteria; and group 4 was comprised of patients diagnosed with MPAL using the EGIL classification only.RESULTS:
We found a significantly worse disease-free survival (groups 1-4) and overall survival (OS) (groups 2 and 3) when comparing MPAL patients to other acute leukemia (AL) patients. A significantly better OS was obtained in patients (groups 2-4) treated with ALL-type chemotherapy compared to acute myeloid leukemia (AML)-type regimens.CONCLUSION:
In light of these results, and because a trend (P=0.06) was found with regard to a better OS in group 4 when compared to other AL patients, an argument can be made that the 2008/2016 WHO classification is underpowered to diagnose all MPAL cases, potentially resulting in the suboptimal treatment of some individuals with AL.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
World Health Organization
/
Leukemia, Myeloid, Acute
/
Leukemia
/
Classification
/
Disease-Free Survival
/
Drug Therapy
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Limits:
Humans
Language:
English
Journal:
Blood Research
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS